Papandreou, ChristopherBullo, MonicaTinahones, Francisco JMartinez-Gonzalez, Miguel AngelCorella, DoloresFragkiadakis, Georgios ALopez-Miranda, JoseEstruch, RamonFito, MontserratSalas-Salvado, Jordi2023-01-252023-01-252017-08-16Papandreou C, Bullò M, Tinahones FJ, Martínez-González MÁ, Corella D, Fragkiadakis GA, et al. Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial. Nutr Metab (Lond). 2017 Sep 2;14:581743-7075http://hdl.handle.net/10668/11561Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characterized as NAFLD cases during the follow-up (n = 15); Group 2, characterized as NAFLD during the follow-up (n = 15); Group 3, characterized as NAFLD-reversion during the follow-up (n = 15). At baseline, significantly lower storage and transport lipids (triacylglycerols and cholesteryl esters), several monoetherglycerophosphocholines, acylglycerophosphocholines, ceramides and ceramide to sphingomyelin ratio (P  The rearrangement of lipid biosynthesis and serum transport may indicate predisposition to NAFLD development. Despite an expected reduction of hepatic lipotoxicity and improved hepatic function in the participants of the study characterized as NAFLD-reversing, the side effects of NAFLD in serum metabolic profiles remained present.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Fatty acid metabolismHepatic lipotoxicityMetabolomicsNon-alcoholic fatty liver diseaseNon-alcoholic fatty liver diseaseSphingomyelinsCholesterol estersProspective studiesCeramidesTriglyceridesMetabolomeMass spectrometryChromatographyresearch article28878811open accessCeramidasCromatografíaEnfermedad del hígado graso no alcohólicoEsfingomielinasEspectrometría de masasEstudios prospectivosMetabolomaTriglicéridosÉsteres del colesterol10.1186/s12986-017-0213-3PMC5581927https://doi.org/10.1186/s12986-017-0213-3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581927/pdf